Navigation Links
Nature's Bioceuticals Finalizes Agreement for the Purchase of Proprietary Weight Loss Formula

CAPE CORAL, Fla., Nov. 11, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures, Inc. ( - News) announced that it has finalized an agreement to purchase all rights to a novel Weight loss formula. The inventor, in order to protect his privacy, has requested that the purchase price not be publicized. With an overall market of over $68 billion in 2010, weight loss is a booming business that continues to grow even in tough economic times. Dieters in the current economy continue to shift to less costly retail and do-it-yourself options such as: meal replacements, OTC diet pills, mail order plans, diet websites, and fad diet books. This trend is very positive for us and we are excited to enter this market by storm.

According to government data, 66% of the 229.5 million American adults are now overweight, or 151 million people, of which 71 million are considered obese. These are the people that are in greater and more immediate danger of developing obesity-related health complications such as heart attacks or diabetes. The larger group of 158 million overweight Americans constitutes the share, for whom their overweight condition is not life threatening; i.e. they're concerned with cosmetic weight loss to help them look and feel better.

According to surveys of American dieting habits performed by the Calorie Control Council, there are 72 million Americans on some kind of diet program. Male – 40% (28.8 million) Female – 60% (43.2 million).

Robert deZanger, CEO of Natures Bioceuticals stated, "We are really excited to enter the weight loss arena with a very special product that will provide people a needed product that will help them lose weight. Our product contains a proprietary blend of natural herbs that has caused weight loss in all people that have tried it. The formula simply curbs the appetite and speeds up the metabolism of those who take it. There is no jittery feeling associated with the product. People who take the formula notice no change in the way they feel. They simply are not as hungry and lose weight. There are many weight loss products on the market and the competition is fierce. We anticipate competition from at least one and probably several new prescription diet drugs that are likely to be approved for sale in the U.S. However, there is an ever increasing trend of people seeking natural remedies as the facts about the dangers of many prescription drugs come to light. Obviously this is a huge market and capturing a small percentage can generate substantial profits for the company. We feel that we have a special product that will be well received and take off as people realize that it works. Further, management feels that the ban by the FDA of products with Ephedra and the negative press on other products containing similar 'stimulants' have left many people desperate to lose weight searching for an alternative."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA".

In addition to historical information, this release contains forward-looking statements.  Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement.  Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact: Financial Insights
Phone Number: 888 656 3509

SOURCE Mistral Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
2. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
3. Natures Bioceuticals Finalizes The Purchase of Cold and Flu Formula
4. Natures Bioceuticals Tears Into the Multi-Billion Dollar Chronic Kidney Disease Market
5. FDA Finalizes Regulation For Certain Software, Hardware Used With Medical Devices
6. Scott & White Finalizes College Station Land Deal
7. Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd.
8. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
9. Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
10. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
11. International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about the ... had high blood pressure due to loud noises," she said, "so I decided that ... pollution as well as radio waves and microwaves." , The baby BABY MUFF prevents ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell of Peconic ... on Long Island’s east end. During the broadcast, entitled “Eyes: the Window to the ... glaucoma and cataracts, and how a visit with his grandmother to her physician put ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors ... independent living, assisted living and all other retirement options. Support for issues surrounding ... research remains a top priority. , So it’s no surprise that every ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that they are showcasing ... dentists to make complex business decisions by providing the tools and information they need ... survey with 10 procedures customized by zip code. , The Sikka Software Ecosystem ...
Breaking Medicine News(10 mins):